Extended Data Fig. 6: Efficacy of different antiviral treatments against MRCoV infection.
From: A MERS-CoV-like mink coronavirus uses ACE2 as an entry receptor
a, Dose-dependent inhibition of MRCoV and SARS-CoV-2 GFP/ΔN by SARS-CoV-2 specific antisera (n = 5). Data from one of three independent experiments are shown. b, Antiviral activities of small molecule SARS-CoV-2 inhibitors NHC (β-D-N4-hydroxycytidine) and PF-07321332 (nirmatrelvir) against MRCoV and SARS-CoV-2 GFP/ΔN. Data are presented as the mean ± s.d. of three independent experiments. (a,b), MRCoV infection was measured by determination of viral RNA copies in the cell culture supernatants using RT-qPCR; efficiency of SARS-CoV-2 GFP/ΔN infection was quantified using CQ1 confocal imaging cell counter.
